METHOD FOR PREDICTION OF LEUKOCYTE TELOMERE LENGTH WITH UNDERLYING SEX STEROID REPLACEMENT THERAPY IN PATIENTS WITH TURNER SYNDROME OR PREMATURE OVARIAN FAILURE Russian patent published in 2024 - IPC G01N33/49 C12Q1/6841 C12Q1/6851 C12Q1/686 C12Q1/6883 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to endocrinology, obstetrics and gynaecology, gerontology, and can be used to predict telomere length (Z_{Telomere length pred}, kb) with the underlying sex steroid replacement therapy in the cyclic regimen in the patients with Turner syndrome or premature ovarian failure and the evaluation of the efficacy of the sex steroid replacement therapy in the cyclic regimen in the patients. Following parameters are determined: predicted duration of hormone replacement therapy (HRT) with sex steroids (X_{taking HRT}, years), basal telomere length (Y_{Telomere length basal}, kb) at the moment of menopause. Value of Z_{Telomere length pred} is calculated using the formula: Z_{Telomere length pred} = 0.216 × X_{taking HRT} + Y_{Telomere length basal} + 9.49. Basal telomere length (Y_{Telomere length basal}, kb) can be determined as the arithmetic mean between leukocyte telomere length calculated by real-time quantitative PCR and leukocyte telomere length calculated by cytogenetic fluorescent hybridisation in situ. When assessing the effectiveness of the sex steroid replacement therapy in the cyclic mode in the patients with Turner syndrome or premature ovarian failure, telomere length is determined (Y_{Telomere length}, kb) at the evaluation date through X_{taking HRT} years and comparison with the predicted telomere length on the date of starting HRT using the duration of X_{taking HRT} years (Z_{Telomere length pred}, kb). If Y_{Telomere length} is higher, identical or less than 15% lower Z_{Telomere length pred}, then therapy is considered effective. If Y_{Telomere length} is 15% or lower than Z_{Telomere length pred}, then the therapy is considered to be ineffective and the woman is referred to a geriatrician for the correction of the therapy. Telomere length (Y_{Telomere length}, kb) can be determined as the arithmetic mean between leukocyte telomere length calculated by real-time quantitative PCR and leukocyte telomere length calculated by cytogenetic fluorescent hybridisation in situ. Comparison with predicted telomere length (Z_{Telomere length pred}, kb) can be carried out once year for 5 years after the onset of menopause and the beginning of the sex steroid replacement therapy in a cyclic mode.

EFFECT: method provides the possibility of predicting the replicative cell potential – leukocyte telomere length in the patients with Turner syndrome or premature ovarian failure, who have not previously taken HRT, in order to prevent age-associated diseases of a person, by assessing the target personalized indicator of the effectiveness of taking HRT at the initial point – the moment of initiation of HRT, and the end point is 5 years from the moment of HRT initiation, with monitoring frequency once a year by venous sampling and laboratory analysis of the patient’s biological material.

5 cl, 2 ex